

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6719670

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	X4 PHARMACEUTICALS, INC.	05/13/2021
RECEIVING PARTY DATA		
Name:	ADIMAB, LLC	
Street Address:	7 LUCENT DRIVE	
City:	LEBANON	
State/Country:	NEW HAMPSHIRE	
Postal Code:	03766	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Application Number:	16343311	
Application Number:	16343297	
Application Number:	62411500	
Application Number:	62411508	
CORRESPONDENCE DATA		
Fax Number:	(617)502-5002	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-248-5000	
Email:	patentdocket@choate.com	
Correspondent Name:	CHOATE HALL & STEWART LLP	
Address Line 1:	TWO INTERNATIONAL PLACE	
Address Line 4:	BOSTON, MASSACHUSETTS 02110	
ATTORNEY DOCKET NUMBER:	2009186-0241 & 0255	
NAME OF SUBMITTER:	BRENDA HERSCHBACH JARRELL, PHD, JD	
SIGNATURE:	/Brenda Herschbach Jarrell/	
DATE SIGNED:	05/20/2021	
Total Attachments: 10		
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page1.tif		
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page2.tif		
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page3.tif		

source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page4.tif
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page5.tif
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page6.tif
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page7.tif
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page8.tif
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page9.tif
source=2021-05-18 Assignment (X4 to Adimab) - Fully Executed#page10.tif

PATENT ASSIGNMENT

WHEREAS, **X4 Pharmaceuticals, Inc.**, (hereinafter "ASSIGNOR"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at **61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134**, is the owner by assignment, pursuant to an Assignment recorded on December 16, 2019 at Reel/Frame 051287/0708, of patent(s), patent application(s) and the invention(s) listed on Schedule A, including the rights in and to any provisionals, continuations, divisionals, reissues or re-examinations, the corresponding foreign patent applications and foreign patents arising out of the aforementioned patent(s) and patent application(s), any future patents related thereto, in whole or in part, or issuing therefrom, and the inventions described and/or claimed in said patent(s) and patent application(s) (referred to collectively hereinafter as the "PATENT RIGHTS"), and

WHEREAS **Adimab, LLC** (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at **7 Lucent Drive, Lebanon, New Hampshire 03766**, desires to acquire the entire right, title and interest in the PATENT RIGHTS, in accordance with agreements entered into with ASSIGNOR;

NOW, THEREFORE, to all whom it may concern be it known that, in exchange for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, as of March 15, 2021 (the "TRANSFER DATE"), ASSIGNOR had sold, assigned, and transferred unto ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the inventions described and/or claimed in said PATENT RIGHTS, including any right of priority thereto, together with ASSIGNOR's entire right, title and interest in and to the patent(s) and patent application(s) listed on Schedule A and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of said patent(s) and patent application(s), and any right, title and interest ASSIGNOR may have had in provisional applications to which said PATENT RIGHTS claim priority; said invention(s), application(s) and patent(s) to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, from the TRANSFER DATE to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby confirms that, as of the TRANSFER DATE, it has conveyed all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment;

AND, ASSIGNOR hereby acknowledges that this assignment, being of its entire right, title and interest in and to said invention(s), application(s) and patent(s), carries with it the right in ASSIGNEE, as of the TRANSFER DATE, to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection

and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;


AND, ASSIGNOR hereby further agrees for itself and its successors, assigns, agents, and legal representatives to provide statements or testimony in any interference or proceeding in which said patent(s) or patent application(s) or invention(s) directed thereto may be involved; to communicate to ASSIGNEE, its successors, assigns and legal representatives, any facts known to ASSIGNOR regarding said invention(s), and to testify in any legal proceedings, sign all lawful papers, make all rightful oaths, and generally execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid inventions to ASSIGNEE, its successors, assignees, and legal representatives, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications, and generally do everything possible to aid ASSIGNEE, its successors, assigns and legal representatives, to obtain, record and enforce full protection for the invention(s) in all countries, but in each instance at ASSIGNEE's reasonable expense;

AND, ASSIGNOR does hereby authorize and request the Director of the United States Patent and Trademark Office and any officials of any country or countries other than the United States, whose duty is to issue patents or other forms of industrial property protection, to issue the same as shall be granted upon any application relating to said PATENT RIGHTS to ASSIGNEE, its successors, assigns, or legal representatives;

AND, ASSIGNOR covenants and agrees that it has and, as of the TRANSFER DATE, it had, full right to convey the entire right, title, and interest assigned, and it has not, and had not as of the TRANSFER DATE, executed, and also that it will not execute in the future, any agreement in conflict herewith;

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE by their duly authorized representative acting on their own free will have caused this instrument to be duly executed and have hereunto set his hand and affixed our seal on the dates set forth below.

The undersigned (whose title is supplied below) is authorized to act on behalf of **X4 Pharmaceuticals, Inc..**

Signature:  Date: 5/13/2021
Name (printed): Derek Meisner
Title (printed): General Counsel

The undersigned (whose title is supplied below) is authorized to act on behalf of **Adimab, LLC**.

Signature: _____ Date: _____

Name (printed): _____

Title (printed): _____

SCHEDULE A

Title: Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
PCT Application (PCT/US17/57720, filed October 20, 2017)
United States Provisional (US 62/411,500, filed October 21, 2016)
United States (US16/343,297)
Australia (AU2017345759)
Brazil (BR1120190080635)
Canada (CA3040886)
China (CN201780074738.4)
European Patent Office (EP17794546.6)
India (IN201917019865)
Israel (IL266101)
Japan (JP2019-521450)
Mexico (MX/a/2019/004448)
New Zealand (NZ753071)
Russia (RU2019115249)
Singapore (SG11201903287P)
South Africa (ZA2019/02545)
South Korea (KR10-2019-7014483)

Title: Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
PCT Application (PCT/US17/57737, filed October 20, 2017)
United States Provisional (US 62/411,508, filed October 21, 2016)
United States (US16/343,311)
Australia (AU2017345786)
Canada (CA3040893)
European Patent Office (EP17794177.0)
Japan (JP2019-521445)

PATENT ASSIGNMENT

WHEREAS, **X4 Pharmaceuticals, Inc.**, (hereinafter "ASSIGNOR"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at **61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134**, is the owner by assignment, pursuant to an Assignment recorded on December 16, 2019 at Reel/Frame 051287/0708, of patent(s), patent application(s) and the invention(s) listed on Schedule A, including the rights in and to any provisionals, continuations, divisionals, reissues or re-examinations, the corresponding foreign patent applications and foreign patents arising out of the aforementioned patent(s) and patent application(s), any future patents related thereto, in whole or in part, or issuing therefrom, and the inventions described and/or claimed in said patent(s) and patent application(s) (referred to collectively hereinafter as the "PATENT RIGHTS"), and

WHEREAS **Adimab, LLC** (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at **7 Lucent Drive, Lebanon, New Hampshire 03766**, desires to acquire the entire right, title and interest in the PATENT RIGHTS, in accordance with agreements entered into with ASSIGNOR;

NOW, THEREFORE, to all whom it may concern be it known that, in exchange for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, as of March 15, 2021 (the "TRANSFER DATE"), ASSIGNOR had sold, assigned, and transferred unto ASSIGNEE, its successors, assigns, and legal representatives, ASSIGNOR'S entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the inventions described and/or claimed in said PATENT RIGHTS, including any right of priority thereto, together with ASSIGNOR's entire right, title and interest in and to the patent(s) and patent application(s) listed on Schedule A and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of said patent(s) and patent application(s), and any right, title and interest ASSIGNOR may have had in provisional applications to which said PATENT RIGHTS claim priority; said invention(s), application(s) and patent(s) to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, from the TRANSFER DATE to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment and sale not been made; ASSIGNOR hereby confirms that, as of the TRANSFER DATE, it has conveyed all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment;

AND, ASSIGNOR hereby acknowledges that this assignment, being of its entire right, title and interest in and to said invention(s), application(s) and patent(s), carries with it the right in ASSIGNEE, as of the TRANSFER DATE, to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection

and the right to procure the grant of all patents to ASSIGNEE in its own name as assignee of ASSIGNOR's entire right, title and interest therein;

AND, ASSIGNOR hereby further agrees for itself and its successors, assigns, agents, and legal representatives to provide statements or testimony in any interference or proceeding in which said patent(s) or patent application(s) or invention(s) directed thereto may be involved; to communicate to ASSIGNEE, its successors, assigns and legal representatives, any facts known to ASSIGNOR regarding said invention(s), and to testify in any legal proceedings, sign all lawful papers, make all rightful oaths, and generally execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid inventions to ASSIGNEE, its successors, assignees, and legal representatives, including the execution of non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications, and generally do everything possible to aid ASSIGNEE, its successors, assigns and legal representatives, to obtain, record and enforce full protection for the invention(s) in all countries, but in each instance at ASSIGNEE's reasonable expense;

AND, ASSIGNOR does hereby authorize and request the Director of the United States Patent and Trademark Office and any officials of any country or countries other than the United States, whose duty is to issue patents or other forms of industrial property protection, to issue the same as shall be granted upon any application relating to said PATENT RIGHTS to ASSIGNEE, its successors, assigns, or legal representatives;

AND, ASSIGNOR covenants and agrees that it has and, as of the TRANSFER DATE, it had, full right to convey the entire right, title, and interest assigned, and it has not, and had not as of the TRANSFER DATE, executed, and also that it will not execute in the future, any agreement in conflict herewith;

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE by their duly authorized representative acting on their own free will have caused this instrument to be duly executed and have hereunto set his hand and affixed our seal on the dates set forth below.


The undersigned (whose title is supplied below) is authorized to act on behalf of **X4 Pharmaceuticals, Inc.**

Signature: _____ Date: _____

Name (printed): _____

Title (printed): _____

The undersigned (whose title is supplied below) is authorized to act on behalf of **Adimab, LLC**.

Signature:  Date: 5-10-2021

Name (printed): ERIC KRAULAND

Title (printed): CHIEF SCIENTIFIC OFFICER

SCHEDULE A

Title: Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
PCT Application (PCT/US17/57720, filed October 20, 2017)
United States Provisional (US 62/411,500, filed October 21, 2016)
United States (US16/343,297)
Australia (AU2017345759)
Brazil (BR1120190080635)
Canada (CA3040886)
China (CN201780074738.4)
European Patent Office (EP17794546.6)
India (IN201917019865)
Israel (IL266101)
Japan (JP2019-521450)
Mexico (MX/a/2019/004448)
New Zealand (NZ753071)
Russia (RU2019115249)
Singapore (SG11201903287P)
South Africa (ZA2019/02545)
South Korea (KR10-2019-7014483)

Title: Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use
PCT Application (PCT/US17/57737, filed October 20, 2017)
United States Provisional (US 62/411,508, filed October 21, 2016)
United States (US16/343,311)
Australia (AU2017345786)
Canada (CA3040893)
European Patent Office (EP17794177.0)
Japan (JP2019-521445)